<![CDATA[Dual Biomarkers and Treatment Sequencing in HR+/HER2− mBC]]>

Neutral

AI Analysis

Summary

Panel discussion explores treatment selection and sequencing strategies for HR+/HER2− metastatic breast cancer patients with dual ESR1 and PI3K pathway alterations, emphasizing individualized therapy based on disease biology and patient factors.

Importance:2/10

Sentiment:

0.00

metastatic breast cancerHR+/HER2−ESR1 alterationsPI3K pathwaytreatment sequencingbiomarkers

Read the original article

Published by Cancer Network on September 17, 2026 12:05 PM

Read Original